BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BGB-B2033 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BGB-B2033\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06427941-2390@assetmemo.bio
DTSTAMP:20261121T005450Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:BGB-B2033: Phase 1/2 readout est. (NCT06427941)
DESCRIPTION:BGB-B2033\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 1/2 Study of BGB-B2033\, Alone or in Combination With Tislelizumab Wi
 th or Without Bevacizumab\, in Participants With Advanced or Metastatic So
 lid Tumors\nEstimated primary completion: 31 March 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/bgb-b2033#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06427941
URL:https://assetmemo.bio/drug/bgb-b2033#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911683-2390@assetmemo.bio
DTSTAMP:20261121T005450Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:BGB-B2033: Phase 2 readout est. (NCT07911683)
DESCRIPTION:BGB-B2033\, phase 2\, Hepatocellular Carcinoma.\nStudy: Study E
 valuating the Efficacy and Safety of BGB-B2033 in Participants With Advanc
 ed Hepatocellular Carcinoma\nEstimated primary completion: 31 March 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/bgb-b2033#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07911683
URL:https://assetmemo.bio/drug/bgb-b2033#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836530-2390@assetmemo.bio
DTSTAMP:20261121T005450Z
DTSTART;VALUE=DATE:20290921
DTEND;VALUE=DATE:20290922
SUMMARY:BGB-B2033: Phase 3 readout est. (NCT07836530)
DESCRIPTION:BGB-B2033\, phase 3\, Hepatocellular Carcinoma.\nStudy: Study C
 omparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular
  Carcinoma\nEstimated primary completion: 21 September 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bgb-b2033#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07836530
URL:https://assetmemo.bio/drug/bgb-b2033#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
